IRIS
PETRONINI, Pier Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.165
AS - Asia 7.819
EU - Europa 7.064
SA - Sud America 1.207
AF - Africa 396
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26.662
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.948
SG - Singapore 3.268
CN - Cina 2.686
IT - Italia 1.308
FI - Finlandia 1.149
IE - Irlanda 1.132
BR - Brasile 999
SE - Svezia 986
DE - Germania 766
HK - Hong Kong 589
UA - Ucraina 541
VN - Vietnam 405
NL - Olanda 293
TR - Turchia 279
ZA - Sudafrica 253
GB - Regno Unito 196
IN - India 162
RU - Federazione Russa 155
CA - Canada 151
FR - Francia 133
AT - Austria 97
AR - Argentina 87
BE - Belgio 84
CI - Costa d'Avorio 71
BD - Bangladesh 57
PL - Polonia 55
KR - Corea 54
JP - Giappone 50
MX - Messico 46
ID - Indonesia 42
EC - Ecuador 40
CZ - Repubblica Ceca 37
ES - Italia 37
IQ - Iraq 33
CO - Colombia 25
IR - Iran 24
PK - Pakistan 24
LT - Lituania 21
MA - Marocco 19
UZ - Uzbekistan 19
VE - Venezuela 18
PS - Palestinian Territory 14
TN - Tunisia 14
JO - Giordania 13
EE - Estonia 12
EG - Egitto 12
AZ - Azerbaigian 11
AE - Emirati Arabi Uniti 10
PY - Paraguay 10
IL - Israele 9
KE - Kenya 9
PE - Perù 9
HU - Ungheria 8
RO - Romania 8
AL - Albania 7
CL - Cile 7
KZ - Kazakistan 7
UY - Uruguay 7
DZ - Algeria 6
KG - Kirghizistan 6
LB - Libano 6
LU - Lussemburgo 6
NP - Nepal 6
SA - Arabia Saudita 6
CH - Svizzera 5
JM - Giamaica 5
QA - Qatar 5
BO - Bolivia 4
CR - Costa Rica 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
AM - Armenia 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
EU - Europa 3
GE - Georgia 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
MY - Malesia 3
NO - Norvegia 3
OM - Oman 3
PA - Panama 3
PT - Portogallo 3
SN - Senegal 3
AO - Angola 2
AU - Australia 2
BH - Bahrain 2
BW - Botswana 2
BY - Bielorussia 2
CY - Cipro 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TJ - Tagikistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
Totale 26.647
Salva come PNG Salva come JPEG
Città #
Singapore 1.700
Ashburn 1.183
Dublin 1.130
Chandler 1.092
Dallas 1.008
Santa Clara 670
Beijing 662
Jacksonville 613
Ann Arbor 597
Hong Kong 584
Dearborn 447
Parma 443
Boardman 363
Nanjing 264
New York 259
Izmir 243
Johannesburg 241
Shanghai 228
Los Angeles 213
Princeton 210
Munich 207
San Mateo 178
Hefei 165
Ho Chi Minh City 146
Wilmington 138
Bremen 128
Helsinki 113
São Paulo 99
Milan 98
Nanchang 98
Kunming 93
Shenyang 92
Chicago 87
Toronto 86
Hebei 85
Moscow 83
Vienna 82
Jinan 81
Hanoi 79
Buffalo 78
Woodbridge 72
Abidjan 71
Brussels 67
Tianjin 64
Columbus 58
Des Moines 55
Seattle 53
Guangzhou 51
Seoul 50
Changsha 49
Marseille 49
Turku 49
Houston 48
Jiaxing 46
Tokyo 42
Bologna 40
Pune 39
Warsaw 39
Frankfurt am Main 38
London 38
Brooklyn 37
The Dalles 37
Norwalk 35
Amsterdam 34
Rio de Janeiro 34
Düsseldorf 32
Modena 32
Rome 32
Jakarta 31
Stockholm 29
Denver 28
Council Bluffs 27
Belo Horizonte 25
Brasília 25
Hangzhou 25
Redmond 24
Reggio Emilia 24
Augusta 23
Fremont 23
Manchester 23
Montreal 23
Phoenix 23
Zhengzhou 23
San Francisco 22
Chennai 20
Leawood 20
Poplar 20
Boston 19
Haiphong 19
Nuremberg 19
Brno 18
San Jose 18
Tashkent 18
Campinas 17
Curitiba 17
Orem 17
Wuhan 17
Wayne 16
Charlotte 15
New Delhi 15
Totale 16.340
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 314
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 229
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 222
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 208
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 206
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 204
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 203
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 192
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 186
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model 183
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 181
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 180
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 172
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 170
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 166
Characterization of gefitinib uptake in NSCLC cell lines 165
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 165
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 165
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 164
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 163
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 161
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 161
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 160
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 160
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 158
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 158
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 158
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 157
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 157
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 156
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 154
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 154
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 153
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 151
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 150
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 150
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 150
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 149
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 149
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 149
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 147
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 147
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 147
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 147
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 147
5-benzylidene-hydantoins as new inhibitors of cell proliferation 145
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 144
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 142
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 142
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 141
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 141
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 141
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 140
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 140
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 139
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 139
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 137
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 137
An original application of plasma expanders: heart-lung preservation. 137
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 136
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 135
Adaptive cellular response to osmotic stress in pig articular chondrocytes 135
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 135
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 134
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 134
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 134
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 134
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 133
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 133
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 132
Induction of betaine/gammabutyric acid transport activity in chondrocytes exposed to hypertonicity 131
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 131
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 131
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 131
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 131
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 130
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 130
New MDR1 inhibitors for overcoming multidrug resistance 130
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 130
SiO2/SiC core-shell nanowires for nanomedicine applications 130
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 130
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 129
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 129
Alterazioni della degradazione proteasoma-dipendente nel corso dell’invecchiamento ed effetti delle restrizioni caloriche 129
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 129
Mannich base derivatives as novel EGFR irreversible inhibitors 127
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 127
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 127
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 126
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 126
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 124
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 124
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 124
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 123
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 123
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 123
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 122
Left lung allotransplantation in the rabbit. An experimental model for assessment of lung preservation 122
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 121
Totale 14.921
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.900
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.900
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021969 0 0 0 0 0 52 148 64 277 55 312 61
2021/20221.057 49 33 48 65 26 12 141 131 62 76 74 340
2022/20234.288 422 456 285 283 433 470 39 274 1.376 28 170 52
2023/20241.843 88 141 59 50 151 456 133 141 65 96 160 303
2024/20255.752 190 298 368 406 555 618 313 236 778 500 510 980
2025/20267.135 1.111 1.163 1.531 1.111 1.610 609 0 0 0 0 0 0
Totale 26.976